Login to Your Account



In The Clinic NEWS
Oncomed Pharmaceuticals Inc.'s stoppage in June of phase Ib trials because of bone-related adverse events with a pair of candidates did little to dampen the enthusiasm of analysts for the firm, and last week's lift of the partial clinical hold on vantictumab (OMP-18R5) only made the picture brighter.
DUBLIN – Dezima Pharma BV is on track to move its highly potent cholesteryl ester transfer protein (CETP) inhibitor TA-8995 (DEZ-001) into a phase III program in the first quarter of next year, following a phase IIb dyslipidemia trial, which the drug passed with flying colors.

Some investor confusion over the results from Repros Therapeutics Inc.'s first of two identical, pivotal phase III trials with Androxal, its oral secondary-hypogonadism treatment, did not stop shares of the company from enjoying an uplift based on the data, which could enable an NDA before 2014 is over.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: